报价延迟最少15分钟:2026/04/22 03:20 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.3 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.14/-0.50
|
|
企业价值
460.79M
|
| 资产负债 |
|
每股账面净值
0.88
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
109.16M
|
|
每股收益
0.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells. |
